Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Compounded GLP-1 Guidepricing database · evidence ledger

Research journal — study summaries & evidence reviews

Plain-language summaries of the clinical trials most often cited in GLP-1 marketing, written to separate what the studies establish from what marketing implies. Every summary describes an FDA-approved product at a studied dose and states explicitly that its results do not transfer to compounded, microdose, or oral formulations. All entries are pending medical review and citation confirmation; specific statistics are not printed as settled until a named reviewer confirms them against the primary source with identifiers.

Pending medical review. The journal publishes summaries in a clearly-labeled provisional state rather than withholding them entirely, so readers can see the evidence framing now. No summary establishes outcomes for any compounded product.